Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 8/20 | 0.70 |
| ▸ | DRD4 | P21917 | 10/20 | 0.62 |
| ▸ | DRD2 | P14416 | 2/20 | 0.56 |
| ▸ | DRD3 | P35462 | 2/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.54 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.51 |
| ▸ | CCR3 | P51677 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6695878 | 0.87 | SIGMAR1 (0.58) | SIGMAR1DRD4DRD2CCR3 | |
| SCHEMBL6704795 | 0.86 | MEN1 (0.51) | SIGMAR1KMT2A | |
| SCHEMBL6694717 | 0.83 | KDM4E (0.60) | SIGMAR1KMT2A | |
| SCHEMBL6702902 | 0.81 | MAPT (0.57) | SIGMAR1DRD4 | |
| SCHEMBL6703098 | 0.81 | KMT2A (0.50) | SIGMAR1DRD4KMT2ACCR3 | |
| SCHEMBL9592361 | 0.80 | DRD4 (0.69) | SIGMAR1DRD4DRD2DRD3MCHR1 | |
| SCHEMBL6702833 | 0.80 | KMT2A (0.51) | SIGMAR1KMT2ACCR3 | |
| SCHEMBL6702012 | 0.80 | DRD4 (0.52) | SIGMAR1DRD4MCHR1 | |
| SCHEMBL6702176 | 0.79 | DRD4 (0.53) | SIGMAR1DRD4KMT2A | |
| SCHEMBL6701288 | 0.78 | RAB9A (0.55) | SIGMAR1MCHR1CCR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040044037-A1 | Amidino-urea serotonin receptor ligands and compositions, their pharmaceutical uses, and methods for their snythesis | HONG YUFENG (US) | 2004-03-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040044037-A1 | Amidino-urea serotonin receptor ligands and compositions, their pharmaceutical uses, and methods for their snythesis | HTR7, HTR1A, HTR2C | SIGMAR1 22/4885DRD4 331/4885DRD2 151/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.